All storiesMetabolic health

Extended Follow-Up of In Vivo BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

Researchers report longer-term results from a study using BCMA CAR-T therapy, delivered directly in the body, to treat patients with relapsed or refractory multiple myeloma. The findings provide insights into durability and safety but require careful interpretation.

NeoMD Editors · 2026-10-11

For information, not personal medical advice. Discuss treatment decisions with a qualified clinician.

The quick read

Key takeaways

In vivo BCMA CAR-T therapy programs a patient’s immune cells directly inside the body to target relapsed or refractory multiple myeloma, differing from conventional lab-modified CAR-T treatments.
Extended follow-up data provide insights into the durability of response and long-term safety of in vivo BCMA CAR-T therapy, though full details on participant numbers and outcomes are not provided.
Further research is needed to confirm benefits, define risks, and validate this potentially less resource-intensive therapy before clinical adoption.

Editorial illustration for Extended Follow-Up of In Vivo BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma — AI-generated editorial illustration.

Background and Findings

Multiple myeloma is a type of blood cancer that affects plasma cells. When standard treatments stop working, it is considered relapsed or refractory, making it harder to treat. CAR-T therapy is a new approach where a patient’s immune cells are engineered to target cancer cells. In this study, scientists evaluated an "in vivo" BCMA CAR-T therapy, meaning the therapy is given directly to the patient to program immune cells inside the body, instead of extracting and modifying cells in the lab.

The report presents extended follow-up data on patients treated with this method. This helps researchers understand how long the treatment effects last and the safety profile over a longer period.

Evidence and Limitations

The evidence comes from a clinical trial of patients with relapsed or refractory multiple myeloma receiving the in vivo BCMA CAR-T therapy. The extended follow-up allows observation of durability of response and side effects.

Supporting editorial illustration for Extended Follow-Up of In Vivo BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma — AI-generated editorial illustration.

However, the full details on the number of participants, length of follow-up, and measures of treatment effectiveness or adverse events are not provided here. Without this information, it is not possible to assess how strong or generalizable the findings are.

As the therapy operates by programming immune cells inside the patient, it differs from conventional CAR-T treatments, which usually involve laboratory modification of cells. Further research is needed to confirm benefits and define risks.

Implications and Next Steps

If confirmed, in vivo BCMA CAR-T therapy might offer a more straightforward and potentially less resource-intensive option for targeting multiple myeloma cells compared to traditional CAR-T approaches. Extended follow-up data are important to ensure the duration of response and long-term safety.

Patients and clinicians should await more detailed results from peer-reviewed publications and regulatory evaluations before considering availability or clinical use.

Source: Nature Medicine